Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 158

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 158
---
ofi”). Dr. Hurlbut served as Head of Protein Conformational Diseases and Rare Pulmonary 116

Diseases Research, where he led a novel strategy focused on discovering small molecules that correct the F508del CFTR mutation. Dr. Munson served as U.S. Head of Medicinal Chemistry and oversaw a diverse group of scientists that advanced multiple development candidates in oncology and rare disease. Shortly after our inception, we entered into an exclusive license agreement with Sanofi to acquire exclusive worldwide rights to research, develop and commercialize certain compounds designed to stabilize NBD1, as well as an ICL4 corrector. In addition, we have assembled a leadership team with deep expertise in drug discovery and developing CF and other rare disease therapies, launching and commercializing therapeutics globally, and building successful public pharmaceutical companies.

| • |     | Mike Cloonan, our President and Chief Executive Officer, has more than 20 years of leadership experience at                                                             
 global organizations, most recently as Chief Operating Officer at Sage Therapeutics, Inc. and prior to that as Senior Vice President of U.S. Commercial at Biogen, Inc. |

| • |     | Charlotte McKee, M.D., our Chief Medical Officer, is a pulmonologist with more than 20 years of drug                                                                                                                                      
 development experience who, while serving as Vice President of CF and Alpha-1 Antitrypsin Deficiency Clinical Development at Vertex, was instrumental in the development and regulatory approvals of three of Vertex’s five approved CFTR 
 modulators, including Trikafta.                                                                                                                                                                                                           |

| • |     | Elena Ridloff, C.F.A., our Chief Financial Officer and Head of                                                                                                                
 Corporate Development, has more than 20 years of experience in finance in the life sciences industry, most recently as Chief Financial Officer at ACADIA Pharmaceuticals Inc. |

Our leadership team is supported by a dedicated team of employees with deep industry-leading expertise, our board of directors, scientific and clinical advisory boards and a group of premier life sciences investors. Since our inception, we have raised approximately $330 million from investors including RA Capital, TPG’s the Rise Fund, Atlas Venture, OrbiMed and Enavate Sciences. We also received founding support from the Cystic Fibrosis Foundation (“CFF”), which has been a committed investor and supporter of our research and development work. Prior to our inception, the CFF spent more than a decade funding early-stage F508del corrector discovery work at Sanofi that contributed to our pipeline